Zevra Competitors
| ZVRA Stock | 8.50 0.10 1.19% |
Zevra Therapeutics vs Gossamer Bio Correlation
Very good diversification
The correlation between Zevra Therapeutics and GOSS is -0.32 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Zevra Therapeutics and GOSS in the same portfolio, assuming nothing else is changed.
Moving against Zevra Stock
| 0.56 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.44 | DXB | Dimerix Earnings Call This Week | PairCorr |
| 0.4 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.36 | VERA | Vera Therapeutics Sell-off Trend | PairCorr |
| 0.33 | SAB | Sonic Healthcare Earnings Call This Week | PairCorr |
Zevra Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Zevra Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Zevra and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Zevra Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Zevra Stock performing well and Zevra Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Zevra Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CRVS | 6.58 | 2.79 | 0.56 | (0.40) | 3.10 | 9.63 | 174.42 | |||
| AKBA | 3.07 | (0.49) | 0.00 | (0.34) | 0.00 | 5.59 | 20.64 | |||
| PRTA | 2.33 | (0.31) | 0.00 | (0.12) | 0.00 | 5.10 | 14.00 | |||
| OLMA | 6.27 | 2.50 | 0.56 | (0.74) | 3.03 | 9.82 | 145.73 | |||
| VTYX | 3.35 | 0.83 | 0.17 | (4.65) | 3.21 | 9.00 | 37.04 | |||
| RIGL | 3.16 | 0.01 | 0.00 | 0.07 | 4.01 | 7.75 | 21.12 | |||
| NAGE | 1.78 | (0.55) | 0.00 | (0.38) | 0.00 | 3.20 | 12.21 | |||
| RGNX | 3.63 | (0.44) | 0.00 | (0.27) | 0.00 | 7.94 | 27.87 | |||
| KALV | 3.38 | 0.49 | 0.12 | 0.43 | 3.55 | 8.43 | 25.15 | |||
| GOSS | 3.95 | (0.03) | (0.01) | (0.01) | 4.83 | 8.77 | 27.11 |
Cross Equities Net Income Analysis
Compare Zevra Therapeutics and related stocks such as Corvus Pharmaceuticals, Akebia Ther, and Prothena plc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (43.2 M) | (41.3 M) | (27 M) | (62.3 M) | (56.1 M) | (58.9 M) |
| AKBA | (8.2 M) | (8.2 M) | (8.2 M) | (13.2 M) | (37 M) | (60.7 M) | (135.7 M) | (76.9 M) | (171.9 M) | (279.7 M) | (349.9 M) | (244.9 M) | (94.2 M) | (51.9 M) | (69.4 M) | (62.5 M) | (65.6 M) |
| PRTA | (12.5 M) | (29.7 M) | (41.4 M) | (41 M) | (7.2 M) | (80.6 M) | (160.1 M) | (153.2 M) | (155.6 M) | (77.7 M) | (111.1 M) | 67 M | (116.9 M) | (147 M) | (122.3 M) | (110.1 M) | (115.6 M) |
| OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (4.3 M) | (22.1 M) | (71.1 M) | (102.6 M) | (96.7 M) | (129.5 M) | (116.5 M) | (110.7 M) |
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.2 M) | (83.7 M) | (108.4 M) | (193 M) | (135.1 M) | (121.6 M) | (127.7 M) |
| RIGL | (12.4 M) | (86 M) | (98.8 M) | (89 M) | (90.9 M) | (51.5 M) | (69.2 M) | (78 M) | (70.5 M) | (66.5 M) | (29.7 M) | (17.9 M) | (58.6 M) | (25.1 M) | 17.5 M | 15.7 M | 16.5 M |
| NAGE | (38.4 K) | (7.9 M) | (11.7 M) | (4.4 M) | (5.4 M) | (2.8 M) | (2.9 M) | (11.4 M) | (33.3 M) | (32.1 M) | (19.9 M) | (27.1 M) | (16.5 M) | (4.9 M) | 8.6 M | 7.7 M | 8.1 M |
| RGNX | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (4 M) | (22.8 M) | (63 M) | (73.2 M) | 99.9 M | (94.7 M) | (111.2 M) | 127.8 M | (280.3 M) | (263.5 M) | (227.1 M) | (204.4 M) | (194.2 M) |
| KALV | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (13.4 M) | (24.8 M) | (18.6 M) | (15.8 M) | (20.8 M) | (29.1 M) | (46.2 M) | (82.3 M) | (92.9 M) | (126.6 M) | (183.4 M) | (24.8 M) | (26.1 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.8 M) | (243.4 M) | (234 M) | (229.4 M) | (179.8 M) | (56.5 M) | (50.9 M) | (53.4 M) |
Zevra Therapeutics and related stocks such as Corvus Pharmaceuticals, Akebia Ther, and Prothena plc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Zevra Therapeutics financial statement analysis. It represents the amount of money remaining after all of Zevra Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Zevra Therapeutics Competitive Analysis
The better you understand Zevra Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Zevra Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Zevra Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Zevra Therapeutics Competition Performance Charts
Five steps to successful analysis of Zevra Therapeutics Competition
Zevra Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Zevra Therapeutics in relation to its competition. Zevra Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Zevra Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Zevra Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Zevra Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Zevra Therapeutics position
In addition to having Zevra Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Software Thematic Idea Now
Software
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Zevra Therapeutics Correlation with its peers. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. Anticipated expansion of Zevra directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zevra Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.47 | Revenue Per Share | Quarterly Revenue Growth 6.054 | Return On Assets | Return On Equity |
Understanding Zevra Therapeutics requires distinguishing between market price and book value, where the latter reflects Zevra's accounting equity. The concept of intrinsic value - what Zevra Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Zevra Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Zevra Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.